Hamamelitannin

• 产品号: 04646
• CAS号: 469-32-9
• 分子式: C20H20O14
• 分子量: 484.3644
• 纯 度: ≥98.0% (HPLC)

产品别名

• 标题: Hamamelitannin
• IUPAC标准名: [(2R,3R,4R)-3,4,5-trihydroxy-4-[(3,4,5-trihydroxybenzoyloxy)methyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate
• IUPAC传统名: [(2R,3R,4R)-3,4,5-trihydroxy-4-[(3,4,5-trihydroxybenzoyloxy)methyl]oxolan-2-yl]methyl 3,4,5-trihydroxybenzoate
• 别名: 2-C-(Hydroxymethyl)-D-ribofuranose 2′,5-digallate; Hamamelofuranose 2′,5-digallate

产品登记号

• CAS号: 469-32-9
• EC号: 207-416-3
• PubChem SID: 24845763
• MDL号: MFCD00017418

产品性质

• Empirical Formula (Hill Notation): C20H20O14
• 纯度: ≥98.0% (HPLC)
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Application
Hamamelitannin can be used to study chromatography, aromatics, esters, hamamelis, heterocyclics, natural compounds, phenols, phytopharma standards, polyhydroxy compounds and tannins. Hamamelitannin significantly reduces biofilm metabolic activity of the following bacteria: Staphylococcus epidermidis, Staphylococcus aureus, Acinetobacter baumannii and Candida albicans strains. Hamamelitannin displays specific cytotoxic activity against colon cancer cells. Hamamelitannin has been used in a study to determine that quorum sensing inhibitors increase the success of antibiotic treatment by increasing the susceptibility of bacterial biofilms and/or by increasing host survival following infection.

详细说明 (简体中文)

Application
Hamamelitannin can be used to study chromatography, aromatics, esters, hamamelis, heterocyclics, natural compounds, phenols, phytopharma standards, polyhydroxy compounds and tannins. Hamamelitannin significantly reduces biofilm metabolic activity of the following bacteria: Staphylococcus epidermidis, Staphylococcus aureus, Acinetobacter baumannii and Candida albicans strains. Hamamelitannin displays specific cytotoxic activity against colon cancer cells. Hamamelitannin has been used in a study to determine that quorum sensing inhibitors increase the success of antibiotic treatment by increasing the susceptibility of bacterial biofilms and/or by increasing host survival following infection.